Pharmaceutical Product Information
Tarceva® (erlotinib)
Notice of Divestment: Tarceva® (erlotinib) 150 mg and 100mg Tablets
Roche has completed the global divestment of Tarceva® to CHEPLAPHARM Schweiz GmbH. The Package Insert (PI) below reflects the last Roche-owned version approved by Health Sciences Authority (HSA), prior to the transfer of ownership. To access the latest PI, please contact CHEPLAPHARM’s appointed local product registrant and distributor in Singapore, Zuellig Pharma Pte Ltd.
Healthcare Professionals
Should you face issues with accessing the product information, please contact us via tel: +65-6735 0550 or click here